New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
Go back to New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1164.89 +11.96 (1.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1152.93 | 52 Week High | $88.16 | |||
| Open | $1144.49 | 52 Week Low | $67.88 | |||
| Day High | $1170.90 | P/E | 269.65 | |||
| Day Low | $1134.41 | EPS | $4.32 | |||
| Volume | 2,479,448 | |||||
